0

Primary Immunodeficiency Therapeutics Market by Disease Type and Geography - Forecast and Analysis 2022-2026

  • Published: May 2022
  • Pages: 122
  • SKU: IRTNTR73348
Technavio

Purchase this report now and if we publish a new version within 90 days, we will send you a free copy.

Safe and Secure SSL Encrypted
  • 2500.00
  • USD

Based on Technavio's market sizing methodology, the primary immunodeficiency therapeutics market size is predicted to surge by USD 3.13 billion from 2021 to 2026 at a CAGR of 7.73%.

This primary immunodeficiency therapeutics market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. The primary immunodeficiency therapeutics market report offers information on several market vendors, including ADMA Biologics Inc., Astellas Pharma Inc., Baxter International Inc., Bayer AG, Bio Products Laboratory Ltd., Biocon Ltd., Biotest AG, CSL Ltd., Grifols SA, Kedrion Spa, LFB SA, Lupin Ltd., Octapharma AG, Pfizer Inc., Sanquin, and Takeda Pharmaceutical Co. Ltd. among others.

This report further entails primary immunodeficiency therapeutics market segmentations, including:

  • Disease type - Antibody deficiency, cellular immunodeficiency, and innate immune disorders
  • Geography - North America, Europe, Asia, and Rest of World (ROW)

What will the Primary Immunodeficiency Therapeutics Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Primary Immunodeficiency Therapeutics Market Size for the Forecast Period and Other Important Statistics

 

Primary Immunodeficiency Therapeutics Market: Key Drivers, Trends, and Challenges

The increasing prevalence of immunodeficiency diseases is notably driving the primary immunodeficiency therapeutics market growth, although factors such as side effects of immunotherapy may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the primary immunodeficiency therapeutics industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Primary Immunodeficiency Therapeutics Market Driver

  • The increasing prevalence of immunodeficiency diseases is one of the key drivers supporting the primary immunodeficiency therapeutics market growth.
  • Adenosine deaminase deficiency is very rare and is estimated to occur in approximately 1 in 200,000 to 1,000,000 newborns worldwide.
  • According to the data released by the World Health Organization (WHO) in November 2020, around 1.5 million new human immunodeficiency virus (HIV) infections were reported globally.
  • The prevalence of PIDDs in the US is estimated at 1 in 2000 individuals. While quick evaluation by an immunologist is important for timely diagnosis and treatment, these patients are typically first evaluated by other sub-specialists or primary care providers. Thus, the increasing prevalence of immunodeficiency diseases is expected to drive the primary immunodeficiency therapeutics market growth during the forecast period. 

Key Primary Immunodeficiency Therapeutics Market Trend

  • Increasing R&D activities is one of the key primary immunodeficiency therapeutics market trends contributing to the market growth.
  • According to an investigational research study conducted in the US and the UK and supported by the NIH in May 2021, 96% of children receiving new experimental lentiviral gene therapy for immunodeficiency diseases reported restored immune function.
  • R&D will continue to be critical in improving the chances of new primary immunodeficiency treatments and therapies. To achieve a competitive advantage in today's market, companies should ideally focus on the development of custom-made medicines for primary immunodeficiency diseases. 
  • People diagnosed with a primary immunodeficiency disease are benefiting from PIDD R&D, which is improving treatment options for patients, making significant progress in recovery, and improving the quality of life of patients. This, in turn, will fuel the primary immunodeficiency therapeutics market growth during the forecast period.

Key Primary Immunodeficiency Therapeutics Market Challenge

  • Side effects of immunotherapy is one of the challenges hindering the primary immunodeficiency therapeutics market growth.
  • Side effects can occur at any point during and after treatment. Doctors and nurses cannot predict when or if side effects may occur or the severity of those consequences.
  • Immunotherapy side effects vary by treatment type and can also be influenced by the patient's overall health and the location and type of cancer.
  • Some immunotherapies can result in severe, even fatal allergic and inflammatory reactions. Therefore, the side effects of immunotherapy may hinder the growth of the global primary immunodeficiency therapeutics market during the forecast period. 

This primary immunodeficiency therapeutics market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Who are the Major Primary Immunodeficiency Therapeutics Market Vendors?

The report analyzes the market’s competitive landscape and offers information on several market vendors, including:

 

  • ADMA Biologics Inc.
  • Astellas Pharma Inc.
  • Baxter International Inc.
  • Bayer AG
  • Bio Products Laboratory Ltd.
  • Biocon Ltd.
  • Biotest AG
  • CSL Ltd.
  • Grifols SA
  • Kedrion Spa
  • LFB SA
  • Lupin Ltd.
  • Octapharma AG
  • Pfizer Inc.
  • Sanquin
  • Takeda Pharmaceutical Co. Ltd.

 

This statistical study of the primary immunodeficiency therapeutics market encompasses successful business strategies deployed by the key vendors. The primary immunodeficiency therapeutics market is fragmented and the vendors are deploying growth strategies such as partnership, agreement, collaboration, and joint ventures to compete in the market.

Product Insights and News

  • Bayer.com - The company offers primary immunodeficiency therapeutics that enables the body to produce the required proteins itself.
  • Bplgroup.com - The company offers primary immunodeficiency therapeutics that are used in the treatment of chronic viral infectious diseases.
  • Biocon.com - The company offers primary immunodeficiency therapeutics that is widely distributed to normal tissues, including rhe thymus, spleen and skin.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The primary immunodeficiency therapeutics market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Which are the Key Regions for Primary Immunodeficiency Therapeutics Market?

For more insights on the market share of various regions Request for a FREE sample now!

38% of the market’s growth will originate from North America during the forecast period. The US and Canada are the key markets for the primary immunodeficiency therapeutics market in North America. Market growth in this region will be faster than the growth of the market in Rest of World (ROW).

The increasing prevalence of immunodeficiency diseases and technological advancements in genetic and stem cell therapy will facilitate the primary immunodeficiency therapeutics market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

The COVID-19 outbreak in 2020 certainly had a negative impact on the primary immunodeficiency therapeutics market in North America. However, in 2021, the demand for these products rebounded, as manufacturing activities were reopened due to large-scale COVID-19 vaccination drives. These factors are expected to drive the growth of the regional primary immunodeficiency therapeutics market during the forecast period.

What are the Revenue-generating Disease Type Segments in the Primary Immunodeficiency Therapeutics Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The primary immunodeficiency therapeutics market share growth by the antibody deficiency segment will be significant during the forecast period. The most common type of primary immunodeficiency in humans is antibody deficiency. It is a diverse category of diseases that cause the malfunction of one or more components of the immune system. Different parts of the immune system are affected by different types of primary immunodeficiency diseases. Antibody deficiency disorders, also known as humoral immunodeficiency diseases, primarily affect B cells. About half of the patients diagnosed with a primary immunodeficiency disease also have a primary antibody deficiency disorder. Such factors of antibody deficiency will drive the primary immunodeficiency therapeutics market growth during the forecast period.

This report provides an accurate prediction of the contribution of all the segments to the growth of the primary immunodeficiency therapeutics market size and actionable market insights on post COVID-19 impact on each segment.

Parent Market Analysis

Technavio categorizes the global primary immunodeficiency therapeutics market as a part of the pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the primary immunodeficiency therapeutics market during the forecast period.

Primary Immunodeficiency Therapeutics Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the primary immunodeficiency therapeutics market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

 

Primary Immunodeficiency Therapeutics Market Scope

Report Coverage

Details

Page number

120

Base year

2021

Forecast period

2022-2026

Growth momentum & CAGR

Accelerate at a CAGR of 7.73%

Market growth 2022-2026

$ 3.13 billion

Market structure

Fragmented

YoY growth (%)

5.3

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 38%

Key consumer countries

US, Canada, Germany, UK, and China

Competitive landscape

Leading companies, Competitive strategies, Consumer engagement scope

Key companies profiled

ADMA Biologics Inc., Astellas Pharma Inc., Baxter International Inc., Bayer AG, Bio Products Laboratory Ltd., Biocon Ltd., Biotest AG, CSL Ltd., Grifols SA, Kedrion Spa, LFB SA, Lupin Ltd., Octapharma AG, Pfizer Inc., Sanquin, and Takeda Pharmaceutical Co. Ltd.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Primary Immunodeficiency Therapeutics Market Report?

  • CAGR of the market during the forecast period 2022-2026
  • Detailed information on factors that will drive primary immunodeficiency therapeutics market growth during the next five years
  • Precise estimation of the primary immunodeficiency therapeutics market size and its contribution to the parent market
  • Accurate predictions on upcoming trends and changes in consumer behavior
  • The growth of the primary immunodeficiency therapeutics industry across North America, Europe, Asia, and Rest of World (ROW)
  • A thorough analysis of the market’s competitive landscape and detailed information on vendors
  • Comprehensive details of factors that will challenge the growth of primary immunodeficiency therapeutics market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

Read More Read Less

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Disease Type
    • Exhibit 06: Executive Summary – Chart on Incremental Growth
    • Exhibit 07: Executive Summary – Data Table on Incremental Growth
    • Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 09: Parent market
    • Exhibit 10: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 11: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 12: Market segments
  • 3.3 Market size 2021
    • 3.4 Market outlook: Forecast for 2021-2026
      • Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
      • Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
      • Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
      • Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

    4 Five Forces Analysis

    • 4.1 Five forces summary
      • Exhibit 17: Five forces analysis - Comparison between 2021 and 2026
    • 4.2 Bargaining power of buyers
      • Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026
    • 4.3 Bargaining power of suppliers
      • Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
    • 4.4 Threat of new entrants
      • Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026
    • 4.5 Threat of substitutes
      • Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026
    • 4.6 Threat of rivalry
      • Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026
    • 4.7 Market condition
      • Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

    5 Market Segmentation by Disease Type

    • 5.1 Market segments
      • Exhibit 24: Chart on Disease Type - Market share 2021-2026 (%)
      • Exhibit 25: Data Table on Disease Type - Market share 2021-2026 (%)
    • 5.2 Comparison by Disease Type
      • Exhibit 26: Chart on Comparison by Disease Type
      • Exhibit 27: Data Table on Comparison by Disease Type
    • 5.3 Antibody deficiency - Market size and forecast 2021-2026
      • Exhibit 28: Chart on Antibody deficiency - Market size and forecast 2021-2026 ($ million)
      • Exhibit 29: Data Table on Antibody deficiency - Market size and forecast 2021-2026 ($ million)
      • Exhibit 30: Chart on Antibody deficiency - Year-over-year growth 2021-2026 (%)
      • Exhibit 31: Data Table on Antibody deficiency - Year-over-year growth 2021-2026 (%)
    • 5.4 Cellular immunodeficiency - Market size and forecast 2021-2026
      • Exhibit 32: Chart on Cellular immunodeficiency - Market size and forecast 2021-2026 ($ million)
      • Exhibit 33: Data Table on Cellular immunodeficiency - Market size and forecast 2021-2026 ($ million)
      • Exhibit 34: Chart on Cellular immunodeficiency - Year-over-year growth 2021-2026 (%)
      • Exhibit 35: Data Table on Cellular immunodeficiency - Year-over-year growth 2021-2026 (%)
    • 5.5 Innate immune disorders - Market size and forecast 2021-2026
      • Exhibit 36: Chart on Innate immune disorders - Market size and forecast 2021-2026 ($ million)
      • Exhibit 37: Data Table on Innate immune disorders - Market size and forecast 2021-2026 ($ million)
      • Exhibit 38: Chart on Innate immune disorders - Year-over-year growth 2021-2026 (%)
      • Exhibit 39: Data Table on Innate immune disorders - Year-over-year growth 2021-2026 (%)
    • 5.6 Market opportunity by Disease Type
      • Exhibit 40: Market opportunity by Disease Type ($ million)

    6 Customer Landscape

    • 6.1 Customer landscape overview
      • Exhibit 41: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    7 Geographic Landscape

    • 7.1 Geographic segmentation
      • Exhibit 42: Chart on Market share by geography 2021-2026 (%)
      • Exhibit 43: Data Table on Market share by geography 2021-2026 (%)
    • 7.2 Geographic comparison
      • Exhibit 44: Chart on Geographic comparison
      • Exhibit 45: Data Table on Geographic comparison
    • 7.3 North America - Market size and forecast 2021-2026
      • Exhibit 46: Chart on North America - Market size and forecast 2021-2026 ($ million)
      • Exhibit 47: Data Table on North America - Market size and forecast 2021-2026 ($ million)
      • Exhibit 48: Chart on North America - Year-over-year growth 2021-2026 (%)
      • Exhibit 49: Data Table on North America - Year-over-year growth 2021-2026 (%)
    • 7.4 Europe - Market size and forecast 2021-2026
      • Exhibit 50: Chart on Europe - Market size and forecast 2021-2026 ($ million)
      • Exhibit 51: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
      • Exhibit 52: Chart on Europe - Year-over-year growth 2021-2026 (%)
      • Exhibit 53: Data Table on Europe - Year-over-year growth 2021-2026 (%)
    • 7.5 Asia - Market size and forecast 2021-2026
      • Exhibit 54: Chart on Asia - Market size and forecast 2021-2026 ($ million)
      • Exhibit 55: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
      • Exhibit 56: Chart on Asia - Year-over-year growth 2021-2026 (%)
      • Exhibit 57: Data Table on Asia - Year-over-year growth 2021-2026 (%)
    • 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
      • Exhibit 58: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
      • Exhibit 59: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
      • Exhibit 60: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
      • Exhibit 61: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
    • 7.7 US - Market size and forecast 2021-2026
      • Exhibit 62: Chart on US - Market size and forecast 2021-2026 ($ million)
      • Exhibit 63: Data Table on US - Market size and forecast 2021-2026 ($ million)
      • Exhibit 64: Chart on US - Year-over-year growth 2021-2026 (%)
      • Exhibit 65: Data Table on US - Year-over-year growth 2021-2026 (%)
    • 7.8 Germany - Market size and forecast 2021-2026
      • Exhibit 66: Chart on Germany - Market size and forecast 2021-2026 ($ million)
      • Exhibit 67: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
      • Exhibit 68: Chart on Germany - Year-over-year growth 2021-2026 (%)
      • Exhibit 69: Data Table on Germany - Year-over-year growth 2021-2026 (%)
    • 7.9 China - Market size and forecast 2021-2026
      • Exhibit 70: Chart on China - Market size and forecast 2021-2026 ($ million)
      • Exhibit 71: Data Table on China - Market size and forecast 2021-2026 ($ million)
      • Exhibit 72: Chart on China - Year-over-year growth 2021-2026 (%)
      • Exhibit 73: Data Table on China - Year-over-year growth 2021-2026 (%)
    • 7.10 UK - Market size and forecast 2021-2026
      • Exhibit 74: Chart on UK - Market size and forecast 2021-2026 ($ million)
      • Exhibit 75: Data Table on UK - Market size and forecast 2021-2026 ($ million)
      • Exhibit 76: Chart on UK - Year-over-year growth 2021-2026 (%)
      • Exhibit 77: Data Table on UK - Year-over-year growth 2021-2026 (%)
    • 7.11 Canada - Market size and forecast 2021-2026
      • Exhibit 78: Chart on Canada - Market size and forecast 2021-2026 ($ million)
      • Exhibit 79: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
      • Exhibit 80: Chart on Canada - Year-over-year growth 2021-2026 (%)
      • Exhibit 81: Data Table on Canada - Year-over-year growth 2021-2026 (%)
    • 7.12 Market opportunity by geography
      • Exhibit 82: Market opportunity by geography ($ million)

    8 Drivers, Challenges, and Trends

    • 8.1 Market drivers
      • 8.2 Market challenges
        • 8.3 Impact of drivers and challenges
          • Exhibit 83: Impact of drivers and challenges in 2021 and 2026
        • 8.4 Market trends

          9 Vendor Landscape

          • 9.1 Overview
            • 9.2 Vendor landscape
              • Exhibit 84: Overview on Criticality of inputs and Factors of differentiation
            • 9.3 Landscape disruption
              • Exhibit 85: Overview on factors of disruption
            • 9.4 Industry risks
              • Exhibit 86: Impact of key risks on business

            10 Vendor Analysis

            • 10.1 Vendors covered
              • Exhibit 87: Vendors covered
            • 10.2 Market positioning of vendors
              • Exhibit 88: Matrix on vendor position and classification
            • 10.3 Bayer AG
              • Exhibit 89: Bayer AG - Overview
              • Exhibit 90: Bayer AG - Business segments
              • Exhibit 91: Bayer AG - Key offerings
              • Exhibit 92: Bayer AG - Segment focus
            • 10.4 Bio Products Laboratory Ltd.
              • Exhibit 93: Bio Products Laboratory Ltd. - Overview
              • Exhibit 94: Bio Products Laboratory Ltd. - Product / Service
              • Exhibit 95: Bio Products Laboratory Ltd. - Key offerings
            • 10.5 Biocon Ltd.
              • Exhibit 96: Biocon Ltd. - Overview
              • Exhibit 97: Biocon Ltd. - Business segments
              • Exhibit 98: Biocon Ltd. - Key offerings
              • Exhibit 99: Biocon Ltd. - Segment focus
            • 10.6 Biotest AG
              • Exhibit 100: Biotest AG - Overview
              • Exhibit 101: Biotest AG - Business segments
              • Exhibit 102: Biotest AG - Key offerings
              • Exhibit 103: Biotest AG - Segment focus
            • 10.7 CSL Ltd.
              • Exhibit 104: CSL Ltd. - Overview
              • Exhibit 105: CSL Ltd. - Business segments
              • Exhibit 106: CSL Ltd. - Key news
              • Exhibit 107: CSL Ltd. - Key offerings
              • Exhibit 108: CSL Ltd. - Segment focus
            • 10.8 Grifols SA
              • Exhibit 109: Grifols SA - Overview
              • Exhibit 110: Grifols SA - Business segments
              • Exhibit 111: Grifols SA - Key offerings
              • Exhibit 112: Grifols SA - Segment focus
            • 10.9 Kedrion Spa
              • Exhibit 113: Kedrion Spa - Overview
              • Exhibit 114: Kedrion Spa - Product / Service
              • Exhibit 115: Kedrion Spa - Key offerings
            • 10.10 Octapharma AG
              • Exhibit 116: Octapharma AG - Overview
              • Exhibit 117: Octapharma AG - Product / Service
              • Exhibit 118: Octapharma AG - Key offerings
            • 10.11 Pfizer Inc.
              • Exhibit 119: Pfizer Inc. - Overview
              • Exhibit 120: Pfizer Inc. - Product / Service
              • Exhibit 121: Pfizer Inc. - Key news
              • Exhibit 122: Pfizer Inc. - Key offerings
            • 10.12 Takeda Pharmaceutical Co. Ltd.
              • Exhibit 123: Takeda Pharmaceutical Co. Ltd. - Overview
              • Exhibit 124: Takeda Pharmaceutical Co. Ltd. - Product / Service
              • Exhibit 125: Takeda Pharmaceutical Co. Ltd. - Key news
              • Exhibit 126: Takeda Pharmaceutical Co. Ltd. - Key offerings

            11 Appendix

            • 11.1 Scope of the report
              • 11.2 Inclusions and exclusions checklist
                • Exhibit 127: Inclusions checklist
                • Exhibit 128: Exclusions checklist
              • 11.3 Currency conversion rates for US$
                • Exhibit 129: Currency conversion rates for US$
              • 11.4 Research methodology
                • Exhibit 130: Research methodology
                • Exhibit 131: Validation techniques employed for market sizing
                • Exhibit 132: Information sources
              • 11.5 List of abbreviations
                • Exhibit 133: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              TechnavioINFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases
              Technavio

              TechnavioDATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts
              Technavio

              TechnavioREPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape
              Interested in this report?
              Get your FREE sample now!
              The primary immunodeficiency therapeutics market market growth will increase by $$ 3.13 bn during 2023-2026.
              The primary immunodeficiency therapeutics market market is expected to grow at a CAGR of 7.73% during 2023-2026.
              Technavio has segmented the primary immunodeficiency therapeutics market market by other 1 (Antibody deficiency, Cellular immunodeficiency, and Innate immune disorders) and geography (North America, Europe, Asia, and Rest of World (ROW)).
              ADMA Biologics Inc., Astellas Pharma Inc., Baxter International Inc., Bayer AG, Bio Products Laboratory Ltd., Biocon Ltd., Biotest AG, CSL Ltd., Grifols SA, Kedrion Spa, LFB SA, Lupin Ltd., Octapharma AG, Pfizer Inc., Sanquin, Takeda Pharmaceutical Co. Ltd. are a few of the key vendors in the primary immunodeficiency therapeutics market market.
              North America will register the highest growth rate of 38% among the other regions. Therefore, the primary immunodeficiency therapeutics market market in North America is expected to garner significant business opportunities for the vendors during the forecast period.
              The key factors driving the primary immunodeficiency therapeutics market market growth are:
              • Increasing prevalence of immunodeficiency diseases

                During the forecast period, the increased prevalence of immunodeficiency diseases is expected to fuel the growth of the global primary immunodeficiency therapeutics market. Adenosine deaminase deficiency is very rare and is estimated to occur in approximately 1 in 200,000 to 1,000,000 newborns worldwide. This disorder is responsible for approximately 15% of severe combined immunodeficiency syndrome (SCID) cases. Furthermore, according to the data released by the World Health Organization (WHO) in November 2020, around 1.5 million new human immunodeficiency virus (HIV) infections were reported globally, with 37.6 million people living with HIV. HIV causes acquired immunodeficiency disorder syndrome (AIDS). The prevalence of PIDDs in the US is estimated at 1 in 2000 individuals. While quick evaluation by an immunologist is important for timely diagnosis and treatment, these patients are typically first evaluated by other sub-specialists or primary care providers. Thus, the increasing prevalence of immunodeficiency diseases is expected to fuel the market growth during the forecast period.


              • Increasing R&D activities

                During the forecast period, the market is expected to rise due to an increase in the number of R and D initiatives by vendors aimed at enhancing the efficacy of immunodeficiency therapeutics. According to an investigational research study conducted in the US and the UK and supported by the NIH in May 2021, 96% of children receiving new experimental lentiviral gene therapy for immunodeficiency diseases reported restored immune function. R and D will continue to be critical in improving the chances of new primary immunodeficiency treatments and therapies. To achieve a competitive advantage in today's market, companies should ideally focus on the development of custom-made medicines for primary immunodeficiency diseases. 

                Because of the severity of PIDDs, prominent manufacturers have increased their R and D efforts for primary immunodeficiency. The adoption of novel therapeutics in primary immunodeficiency is being aided by R and D activities for new technology for primary immunodeficiency therapeutics. People diagnosed with a primary immunodeficiency disease are benefiting from PIDD R and D, which is improving treatment options for patients, making significant progress in recovery, and improving the quality of life of patients. R and D initiatives are aimed toward a specific immunodeficiency and can include stem cell, bone marrow, and thymus transplants, immunoglobulin (antibody) replacements, antibiotic resistance prevention, and autoimmune disease management strategies.


              The primary immunodeficiency therapeutics market market vendors should focus on grabbing business opportunities from the antibody deficiency segment as it accounted for the largest market share in the base year.
              Safe and Secure SSL Encrypted
              Technavio

              Single User:

              2500 USD

              Technavio Get the report (PDF) sent to your email within minutes.

              Subscribe & Save

              Get lifetime access to our
              Technavio Insights

              Want to customize this report?

              This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.

              We offer $1000 worth of FREE customization at the time of purchase
              Technavio
              Enquire Before Buying
              1. Home
              2. Health Care
              3. Published Report
              17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>